- Today's listing of AddLife means that we’re now a stand-alone company, a defined Life Science player, in the Nordic countries. It’s our opening-day on the stock exchange but AddLife rests on hundred year of history as a spin-off from Bergman & Beving and Addtech. We’ll now be able to fully focus on continuous profitable growth both organically and through acquisitions. Independent players within the Life Science sector is well-needed to meet the growing market demands and challenges given what the healthcare sector is facing, says Kristina Willgård, CEO AddLife AB.
AddLife AB currently holds 25 subsidiaries with clients operating in the healthcare, laboratories and research in the private and public sectors. AddLife provides high-quality technology products, services and qualified advice in all Nordic markets. Subsidiaries are all niche in specific specialist areas and acts as a link between supplier and customer. AddLife consists of two business areas; Labtech and Medtech.
Through the IPO AddLife expects an increased exposure to attract more talents and more acquisition candidates as a defined Life Science company. Market growth within the Nordic Life Science industry is positive, and several macro trends point to continued future growth.
For more information please contact:
Kristina Willgård, CEO
+46 70 510 12 23